Results 291 to 300 of about 1,190,584 (342)

Resectable non-small cell lung cancer in women: A disease-specific entity? [PDF]

JTCVS Open
Sewell M, Boerner T, Toumbacaris N, Tan KS, Choe G, Harrington C, Sihag S, Adusumilli PS, Bott MJ, Downey RJ, Huang J, Isbell JM, Park BJ, Rocco G, Gray K, Rusch VW, Jones DR, Molena D.   +17 more
europepmc   +1 more source

Doxorubicin‐Loaded Metal–Organic Framework for Ferroptosis‐Enhanced Chemotherapy Through Sustained Zn Release and Glutathione Peroxidase Downregulation

Advanced Healthcare Materials, EarlyView.
A robust zinc‐based metal–organic framework (ZnMOF) enables dual functions of doxorubicin delivery and sustained Zn2+ release to trigger ferroptosis‐enhnaced chemotherapy. DOX@ZnMOF effectively depletes intracellular glutathione, suppresses GPX4, and elevates reactive oxygen species, leading to efficient oxidative DNA damage and apoptosis.
Xin Ma, Chenghua Deng, Chaoyu Wang, Langston Tilman, Jinhong Li, Wenbin Lin   +5 more
wiley   +1 more source

CircRNA signature predicts immunotherapy response in advanced non-small cell lung cancer. [PDF]

Ther Adv Med Oncol
Li X, Wang S, Cui Y, Jin SH, Xu J, Zhang C, Shen J, Ma H, Zhou JG.   +8 more
europepmc   +1 more source

Strategies to Improve the Lipophilicity of Hydrophilic Macromolecular Drugs

Advanced Healthcare Materials, EarlyView.
Hydrophilic macromolecular drugs can be successfully lipidized by covalent attachment of lipids, by hydrophobic ion pairing with negatively or positively charged surfactants, and by dry or wet reverse micelle formation. Lipophilicity enhancement of hydrophilic macromolecules has several benefits including stability and bioavailability improvement ...
Sera Lindner, Stefan Keim, Soheil Haddadzadegan, Odile Fernandez Romero, Katrin Zöller, Gabriel Stern, Ilaria Cesi, Krum Kafedjiiski, Andreas Bernkop‐Schnürch   +8 more
wiley   +1 more source

Chemo-Radio-Immunotherapy Strategies to Prevent Immune Resistance in Non-Small Cell Lung Cancer. [PDF]

Cancers (Basel)
Rusu-Patraulea RA, Rusu P, Ciuleanu TE.
europepmc   +1 more source

Targeting Growth Hormone Receptor to Overcome Therapy Resistance in Non-Small Cell Lung Cancer. [PDF]

Int J Mol Sci
Ahmad A, Basu R, Fyffe C, Geiger R, Walsh C, Minto D, Brenya E, Alur AV, Neggers SJCMM, Kopchick JJ.   +9 more
europepmc   +1 more source

Non-small cell lung cancer molecular subtypes and vulnerability to immunotherapy treatment combinations. [PDF]

Nat Commun
Lu T, Hamidi H, Socinski MA, Reck M, Cappuzzo F, Barlesi F, Jotte RM, Müller S, Qamra A, Amitai A, Guan X, Fuentes E, Koeppen H, Giltnane JM, Shames DS, Ballinger M, He MX, Wang Y, Srivastava MK, Nabet BY.   +19 more
europepmc   +1 more source

The Role of Low CD36 Expression in the Development of Non-Small Cell Lung Cancer and Its Potential for Therapy. [PDF]

Cancers (Basel)
Wu R, Xu X, Luo D, Wu J, Chang X, Ma C, Huang B, Fan J, Nie X.   +8 more
europepmc   +1 more source

PRMT3 Drives IDO1-Dependent Radioresistance and Immunosuppression by Promoting Kynurenine Metabolism in Non-Small Cell Lung Cancer. [PDF]

Cancer Res
Zhang S, Wang S, Wang Y, Zhou T, Yang J, Xu J, Li G, Zhang Y, Wang X, Yin H.   +9 more
europepmc   +1 more source